Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Equity Average (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Equity Average for 4 consecutive years, with $266.3 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Equity Average rose 65.96% year-over-year to $266.3 million, compared with a TTM value of $266.3 million through Sep 2023, up 65.96%, and an annual FY2022 reading of $218.6 million, up 920.13% over the prior year.
  • Equity Average was $266.3 million for Q3 2023 at Terns Pharmaceuticals, down from $280.9 million in the prior quarter.
  • Across five years, Equity Average topped out at $282.3 million in Q1 2023 and bottomed at -$118.6 million in Q4 2020.
  • Average Equity Average over 4 years is $124.6 million, with a median of $163.3 million recorded in 2021.
  • Peak annual rise in Equity Average hit 325.87% in 2022, while the deepest fall reached 23.0% in 2022.
  • Year by year, Equity Average stood at -$118.6 million in 2020, then surged by 240.13% to $166.2 million in 2021, then skyrocketed by 38.55% to $230.3 million in 2022, then grew by 15.62% to $266.3 million in 2023.
  • Business Quant data shows Equity Average for TERN at $266.3 million in Q3 2023, $280.9 million in Q2 2023, and $282.3 million in Q1 2023.